SK Bioscience Co Ltd stock (KR7326030004): Recent price dip amid short-term buy signals

SK Bioscience Co Ltd shares fell 0.414% to ?48,150 on July 11, 2025, on the Korea Exchange, showing mixed technical signals with a general buy outlook in a rising trend.

SK Bioscience Co Ltd (KR7326030004) stock declined 0.414% on July 11, 2025, closing at ?48,150 from ?48,350, with intraday volatility of 2.81% between ?48,000 and ?49,350, StockInvest.us as of Jul 11, 2025. The biotech firm, focused on vaccines and biopharmaceuticals, remains in a short-term rising trend, with support levels at ?44,100.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: SK Bioscience Co., Ltd.
• Sector/industry: Biotechnology / Vaccines
• Headquarters/country: South Korea
• Core markets: Asia, global vaccine supply
• Key revenue drivers: Vaccine production, R&D partnerships
• Home exchange/listing venue: Korea Exchange (302440)
• Trading currency: KRW

SK Bioscience Co Ltd: core business model

SK Bioscience Co Ltd develops and manufactures vaccines and biopharmaceuticals, positioning itself as a global partner from prevention to cure. The company operates advanced facilities like the Songdo Global R&D Center, which earned LEED Gold certification for sustainability, SK Bioscience website as of 2026. Its pipeline targets infectious diseases and innovative therapies.

Revenue stems from contract development and manufacturing (CDMO) services alongside proprietary vaccine programs. SK Bioscience collaborates with international partners for technology transfer and commercialization, enhancing its role in global health supply chains relevant to US investors via exposure to biotech innovation.

Main revenue and product drivers for SK Bioscience Co Ltd

Key drivers include vaccine production for COVID-19 and seasonal influenza, with expansion into next-generation biologics. The company's 2026 Q1 preliminary results highlighted external growth and future investments, per its website. These efforts support stable revenue amid fluctuating biotech demands.

Partnerships and orders for vaccine supply bolster financials, while R&D investments drive long-term pipeline value. For US investors, SK Bioscience's global footprint offers indirect exposure to Asia-Pacific biotech growth influencing US markets.

Industry trends and competitive position

The biotech sector sees rising demand for vaccines post-pandemic, with SK Bioscience competing via scalable manufacturing. Its inclusion in ETFs like DB MIGHTY Biosimilar & CDMO Active ETF underscores market recognition, Investing.com as of recent data.

Why SK Bioscience Co Ltd matters for US investors

Listed on the Korea Exchange, SK Bioscience provides US investors access to South Korea's biotech hub, a key player in global vaccine supply chains affecting US pharmaceutical imports and partnerships. Its innovations contribute to worldwide health security, with relevance through Nasdaq-listed peers and ETF holdings.

Conclusion

SK Bioscience Co Ltd maintains a rising trend despite the recent 0.414% dip to ?48,150 on July 11, 2025, with technical buy signals from long-term averages. Ongoing R&D and vaccine focus position it in a dynamic biotech landscape. Investors track support levels and Q1 growth for future developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.